Synendos Therapeutics

Synendos is a neuroscience startup that operates in the pharmaceutical industry, specifically focusing on neuropsychiatric disorders. The company's primary mission is to develop safe and effective therapies that can restore the natural functioning of the brain. The team, led by Dr. Andrea Chicca and Prof. Dr. Jürg Gertsch, both with extensive experience in the pharma industry and research on the endocannabinoid system (ECS), is working on a new drug target within the ECS.

The ECS is a complex cell-signaling system that plays a role in regulating a range of functions and processes, including mood, appetite, sleep, and memory. Synendos' approach to treating neuropsychiatric disorders involves modulating this system to restore the brain's natural functioning.

Their lead drug candidate, SYT-510, is a Selective Endocannabinoid Re-uptake Inhibitor (SERI). In simple terms, SERIs are a new type of drug that can adjust the ECS to help it function better. This is a first-in-class drug, meaning it's the first of a new type of drugs that could potentially open a new way of treating neuropsychiatric disorders.

Synendos' business model revolves around the research, development, and eventual commercialization of these drugs. The company's primary clients would be healthcare providers and patients suffering from neuropsychiatric disorders. The company generates revenue through the sale of its pharmaceutical products once they have been approved for use.

Keywords: Neuroscience, Neuropsychiatric Disorders, Endocannabinoid System, Drug Development, SERIs, Pharmaceutical Industry, Healthcare Providers, Patients, Research, Commercialization.